No products in the cart.
Rabbit Polyclonal Phospho-Met (Y1003) antibody (STJ91076)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, IF, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:40000;
Recommended protocols: check protocols
Click or hover above images to see image description for Met (phospho Tyr1003) Polyclonal Antibody.
Check alternative names for the antibodyExpand
MET antibody,|AUTS9 antibody|c met antibody|D249 antibody|Hepatocyte growth factor receptor antibody|HGF antibody|HGF receptor antibody|HGF/SF receptor antibody|HGFR antibody|MET antibody|Met proto oncogene tyrosine kinase antibody|MET proto oncogene, receptor tyrosine kinase antibody|Met proto-oncogene (hepatocyte growth factor receptor) antibody|Met proto-oncogene antibody|Met protooncogene antibody|MET_HUMAN antibody|Oncogene MET antibody|Par4 antibody|Proto-oncogene c-Met antibody|RCCP2 antibody|Scatter factor receptor antibody|SF receptor antibody|Tyrosine-protein kinase Met antibody|Anti-Met (c-Met) antibody [EP1454Y] (ab51067)
SCBT cat No: sc-10|sc-161|sc-514148|sc-514149|sc-8307|sc-46394|sc-46395|sc-162|sc-47705|sc-12807|sc-293488|sc-164990|sc-168580|sc-514653|sc-376779|
Met (phospho Tyr1003) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Met (Y1003) Polyclonal Antibody detects endogenous levels of Met protein only when phosphorylated at Y1003.
Synthesized phospho-peptide derived from Met (phospho Tyr1003) at AA range 950-1030
WB, IHC, IF, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:40000;
|Molecular weight|| |
Met (phospho Tyr1003) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Met (phospho Tyr1003) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Hepatocyte growth factor receptor antibody, HGF receptor antibody, HGF/SF receptor antibody, Proto-oncogene c-Met antibody, Scatter factor receptor antibody, SF receptor antibody, Tyrosine-protein kinase Met antibody
|Database links|| |
Human UniProt/Swiss-Prot:<a href="http://www.uniprot.org/uniprot/P08581">P08581</a>;Rat UniProt/Swiss-Port: <a href="http://www.uniprot.org/uniprot/P97523">P97523</a>;Human Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene&term=4233">4233</a>;Mouse Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/gene/17295">17295</a>;Rat Entrez Gene: <a href="http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Rn&CID=10617">Rn.10617</a>
|Protein names|| |
Hepatocyte growth factor receptor , HGF receptor , HGF/SF receptor , Proto-oncogene c-Met , Scatter factor receptor , SF receptor , Tyrosine-protein kinase Met
|Protein function|| |
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. / Acts as a receptor for Listeria internalin inlB, mediating entry of the pathogen into cells. / ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. / In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.
|Protein tissue specificity|| |
Expressed in normal hepatocytes as well as in epithelial cells lining the stomach, the small and the large intestine. Found also in basal keratinocytes of esophagus and skin. High levels are found in liver, gastrointestinal tract, thyroid and kidney. Also present in the brain.
|Involvement in disease|| |
Note: Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.; Note: Defects in MET may be associated with gastric cancer.; Hepatocellular carcinoma (HCC) [MIM:114550]: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Renal cell carcinoma papillary (RCCP) [MIM:605074]: A subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Note: A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.; Note: MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.; Deafness, autosomal recessive, 97 (DFNB97) [MIM:616705]: A form of non-syndromic sensorineural hearing loss with prelingual onset. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Osteofibrous dysplasia (OSFD) [MIM:607278]: A congenital disorder of osteogenesis characterized by non-neoplastic, radiolucent lesions that affect the cortical bone immediately under the periosteum. It usually manifests as a painless swelling or anterior bowing of the long bones, most commonly the tibia and fibula. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Disease-associated variants identified in 4 families cause the deletion of exon 14. This results in the exclusion of an ubiquitination target site within the cytoplasmic domain, hence in protein stabilization. The persistent presence of MET at the cell surface in conditions of ligand-dependent activation retards osteoblastic differentiation. .
|Protein sequence and domain|| |
The kinase domain is involved in SPSB1 binding. / The beta-propeller Sema domain mediates binding to HGF. / Belongs to the protein kinase superfamily. Tyr protein kinase family. / Contains 3 IPT/TIG domains. / Contains 1 protein kinase domain. / Contains 1 Sema domain.
|Protein post-translational modifications|| |
Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2. / Ubiquitinated. Ubiquitination by CBL regulates the receptor stability and activity through proteasomal degradation.
|Protein cellular localization|| |
Membrane; Single-pass type I membrane protein / Secreted
|Research area|| |
<a href="http://antibodyplus.com/research-areas/">All research areas</a>><a href="http://antibodyplus.com/Membrane-Receptors/">Membrane Receptors</a>><a href="http://antibodyplus.com/product-tag/Met/">Met</a><br><a href="http://antibodyplus.com/product-tag/Membrane-Receptors/"> (View all antibody categories related to Membrane Receptors)</a>
AntibodyPlus can customize Met (phospho Tyr1003) Antibody according to your requirement, including bulk product size,etc. Please contact <a href="mailto:firstname.lastname@example.org">email@example.com</a>. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: